SBIR Phase I: Biotransformable Block Terpolymers for Drug-Eluting Stents

SBIR 第一阶段：用于药物洗脱支架的生物可转化嵌段三元共聚物

• 批准号: 0712489
• 负责人: Lisa Kemp
• 金额: --
• 依托单位: Ablitech, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-01 至 2008-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0712489&HistoricalAwards=false
• 关键词: SBIR; Phase; Biotransformable; Block; Terpolymers

This Small Business Innovation Research (SBIR) Phase I research research project aims to develop a polymer system for drug eluting coronary stents (DES). The material is expected to provide higher drug loading with a controlled drug release profile, as well as tunable mechanical properties over the lifetime of the stent. This will be accomplished using block terpolymers of specific composition to which drug molecules will be covalently attached. Recent advances in DES technology have increased the success rate of CHD treatment; however, restenosis (re-blockage of the artery through the stent) occurs in 10% of the implanted stents. Also currently available drug eluting coatings deliver the bulk of the loaded drug within the first 48 hours of stent placement, with little to no delivery after 30 days. Thus a new type of stent that can overcome the limitations of current stents would be of significant value.

这个小型企业创新研究(SBIR)第一阶段研究项目旨在开发一种用于药物洗脱冠状动脉支架(DES)的聚合物系统。这种材料有望提供更高的载药量，具有受控的药物释放曲线，以及在支架寿命内可调的机械性能。这将通过使用特定组成的嵌段三元聚合物来实现，药物分子将共价连接到这些嵌段三元聚合物上。DES技术的最新进展提高了CHD治疗的成功率；然而，10%的植入支架会发生再狭窄(通过支架使动脉再次堵塞)。目前可用的药物洗脱涂层在支架放置后的第一个48小时内输送大部分装载的药物，30天后几乎没有输送。因此，一种能够克服现有支架局限性的新型支架将具有重要的价值。